Two rival bidders for <ENAMEX TYPE="ORGANIZATION">Connaught</ENAMEX> Biosciences extended their offers to acquire the <ENAMEX TYPE="LOCATION">Toronto</ENAMEX> based vaccine manufacturer <ENAMEX TYPE="ORGANIZATION">Friday Institut Merieux S A</ENAMEX> which offered 942 million Canadian dollars US 801 2 million or <ENAMEX TYPE="LOCATION">C</ENAMEX> 37 a share for <ENAMEX TYPE="ORGANIZATION">Connaught</ENAMEX> said it would extend its bid due to expire last <ENAMEX TYPE="ORGANIZATION">Thursday</ENAMEX> to Nov 6 <ENAMEX TYPE="LOCATION">A C</ENAMEX> 30 a share bid by <ENAMEX TYPE="ORGANIZATION">Ciba Geigy Ltd</ENAMEX> a pharmaceutical company based in <ENAMEX TYPE="LOCATION">Basel Switzerland</ENAMEX> and <ENAMEX TYPE="LOCATION">California</ENAMEX> based <ENAMEX TYPE="ORGANIZATION">Chiron Corp</ENAMEX> a bioresearch concern was extended to Nov 16 It had been due to expire <ENAMEX TYPE="LOCATION">Friday</ENAMEX> evening <ENAMEX TYPE="ORGANIZATION">Merieux</ENAMEX> previously said it would ensure its bid remained open pending a final decision by Canadian regulators on whether to approve the takeover <ENAMEX TYPE="ORGANIZATION">Merieux</ENAMEX> a vaccine and bioresearch firm based in <ENAMEX TYPE="LOCATION">Lyon France</ENAMEX> is controlled 50 1 by state owned <ENAMEX TYPE="ORGANIZATION">Rhone Poulenc S A</ENAMEX> The Canadian government previously said <ENAMEX TYPE="ORGANIZATION">Merieux</ENAMEX> s bid didn t offer enough net benefit to <ENAMEX TYPE="LOCATION">Canada</ENAMEX> to be approved and gave <ENAMEX TYPE="ORGANIZATION">Merieux</ENAMEX> an until mid November to submit additional information <ENAMEX TYPE="ORGANIZATION">Merieux</ENAMEX> officials said last week that they are highly confident the offer will be approved once it submits details of its proposed investments to federal regulators Both offers are conditional on regulatory approvals and enough shares being tendered to give the bidders a majority of <ENAMEX TYPE="ORGANIZATION">Connaught</ENAMEX> s shares outstanding <ENAMEX TYPE="ORGANIZATION">Institut Merieux</ENAMEX> which already holds a 12 5 stake in <ENAMEX TYPE="ORGANIZATION">Connaught</ENAMEX> said that at the close of business <ENAMEX TYPE="ORGANIZATION">Thursday</ENAMEX> 5 745 188 shares of <ENAMEX TYPE="ORGANIZATION">Connaught</ENAMEX> and <ENAMEX TYPE="LOCATION">C</ENAMEX> 44 3 <ENAMEX TYPE="ORGANIZATION">NNP</ENAMEX> million face amount of debentures convertible into 1 826 596 common shares had been tendered to its offer At the close of business <ENAMEX TYPE="ORGANIZATION">Thursday Ciba Geigy</ENAMEX> and <ENAMEX TYPE="ORGANIZATION">Chiron</ENAMEX> said 11 580 common shares had been tendered to their offer At last report <ENAMEX TYPE="ORGANIZATION">Connaught</ENAMEX> had 21 8 million shares outstanding Separately the <ENAMEX TYPE="ORGANIZATION">Ontario Supreme Court</ENAMEX> said it will postpone indefinitely a ruling on the lawsuit launched by the <ENAMEX TYPE="ORGANIZATION">University</ENAMEX> of <ENAMEX TYPE="LOCATION">Toronto</ENAMEX> against <ENAMEX TYPE="ORGANIZATION">Connaught</ENAMEX> in connection with the <ENAMEX TYPE="ORGANIZATION">Merieux</ENAMEX> bid In a statement prepared by lawyers for the university and <ENAMEX TYPE="ORGANIZATION">Connaught</ENAMEX> the parties said they agreed that as a result of reaching a C415 million research accord It is unnecessary that there be a judgment on the merits of the case at this time <ENAMEX TYPE="ORGANIZATION">Lawyers</ENAMEX> for the two sides weren t immediately available for comment The university had sought an injunction blocking <ENAMEX TYPE="ORGANIZATION">Connaught</ENAMEX> s board from recommending or supporting an offer for the company by <ENAMEX TYPE='untagged'>Merieux</ENAMEX>